✦ LIBER ✦

Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

✍ Scribed by Sofia Jönsson; Bob Olsson; Jenny Söderberg; Hans Wadenvik

Book ID: 113027896
Publisher: Springer
Year: 2011
Tongue: English
Weight: 132 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1359-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response to imatinib therapy in adult pa

Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study

✍ Alsobhi, Enaam; Abrar, Mohammed Burhan; Abdelaal, Mohammed; Alsaeed, Ahmed; Absi 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 761 KB

Investigating factors associated with ad

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

✍ Efficace, F; Baccarani, M; Rosti, G; Cottone, F; Castagnetti, F; Breccia, M; Ali 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 259 KB

Phase 1 study of lonafarnib (SCH 66336)

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

✍ Jorge Cortes; Elias Jabbour; George Q. Daley; Susan O'Brien; Srdan Verstovsek; A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract ## BACKGROUND. Lonafarnib is an orally bioavailable nonpetidomimetic farnesyl transferase inhibitor with significant activity against BCR‐ABL‐positive cell lines and primary human chronic myeloid leukemia (CML) cells. Lonafarnib can inhibit the proliferation of imatinib‐resistant cells

A retrospective analysis of therapy adhe

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting

✍ Guérin, Annie; Chen, Lei; Wu, Eric Q.; Ponce de Leon, Diego; Griffin, James D. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 174 KB

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o